Affiliation
Institute of Cancer Sciences, The Christie and University of Manchester, Withington, Manchester M20 4BX, UKIssue Date
2014-12-03
Metadata
Show full item recordCitation
PARP inhibitors in BRCA mutation-associated ovarian cancer. 2014: Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(14)71172-6PubMed ID
25481790Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(14)71172-6
Scopus Count
Collections
Related articles
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
- Authors: Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M
- Issue date: 2015 Jan
- Made-to-measure medicine: BRCA and gynaecological cancer.
- Authors: Foulkes WD
- Issue date: 2014 Jul
- What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
- Authors: Liu JF, Matulonis UA
- Issue date: 2016 May
- PARP inhibitors plough on.
- Authors: Mullard A
- Issue date: 2017 Mar 30
- PARP inhibitors in cancer: moving beyond BRCA.
- Authors: Telli ML
- Issue date: 2011 Sep